Clinical Trials Directory

Trials / Active Not Recruiting

Active Not RecruitingNCT04229160

Noninvasive 3D Mapping in Persistent Atrial Fibrillation, to Describe Modifications of the Arrhythmogenic Substrate After Pulmonary Vein Isolation and Identify Potential Predicting Factors of Ablation Success

Status
Active Not Recruiting
Phase
N/A
Study type
Interventional
Enrollment
50 (estimated)
Sponsor
University Hospital, Rouen · Academic / Other
Sex
All
Age
18 Years – 75 Years
Healthy volunteers
Not accepted

Summary

Atrial fibrillation (AF) is the most common cardiac arrhythmia in adults. It is a major cause of ischemic stroke and heart failure. Intravascular cardiac ablation of the left atrium by catheter delivery is an efficient treatment to restore sinus rhythm. AF ablation is a class IIa treatment for patients with symptomatic persistent AF refractory or intolerant to antiarrhythmic medication. There are still many debates considering the ablation strategy. The pulmonary veins remain the cornerstone of AF ablation therapy, even in persistent AF. There is a large electrical remodeling occurring in the left atrium between paroxysmal AF, early persistent AF and long-standing persistent AF. However, no multicentric and randomized study has demonstrated so far the interest of targeting other left atrial substrate, such as rotors or focal sources. Our study aims to describe with a noninvasive mapping system the arrhythmogenic substrate of persistent AF \> 6 months pre- and post-cardioversion, and after pulmonary vein isolation.

Conditions

Interventions

TypeNameDescription
DEVICENoninvasive mapping (Cardioinsight® system)Noninvasive mapping (Cardioinsight® system) of the left atria before the Atrial fibrilation ablation procedure
DEVICElong-term cardiac monitoring (LINQ system)long-term cardiac monitoring (LINQ system) is used to evaluate recurrence rate following AF ablation procedure
PROCEDUREAtrial Fibrillation ablation procedureAtrial Fibrillation ablation procedure is done with standard practice

Timeline

Start date
2020-06-09
Primary completion
2025-06-24
Completion
2026-06-24
First posted
2020-01-18
Last updated
2025-09-17

Locations

4 sites across 1 country: France

Source: ClinicalTrials.gov record NCT04229160. Inclusion in this directory is not an endorsement.